NeoGenomics to Present New ctDNA Research at SABCS 2025

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present data on its RaDaR 1.0 assay for molecular residual disease detection at the 2025 San Antonio Breast Cancer Symposium.

Business Wire • Dec 10, 2025

NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present new data at ASH on how comprehensive genomic profiling supports diagnosis and treatment decisions in myeloid malignancies.

Business Wire • Dec 8, 2025

Neo Performance Materials Inc. (NEO:CA) Q3 2025 Earnings Call Transcript

Neo Performance Materials Inc. ( NEO:CA ) Q3 2025 Earnings Call November 14, 2025 10:00 AM EST Company Participants Karen Murray Rahim Suleman - CEO, President & Director Jonathan Baksh - Executive VP & CFO Conference Call Participants Daniel Harriman - Sidoti & Company, LLC Nicholas Boychuk - Cormark Securities Inc., Research Division Ian Gillies - Stifel Nicolaus Canada Inc., Research Division Presentation Operator Good morning, and welcome to the Neo Performance Materials Third Quarter 2025 Earnings Conference Call. For opening remarks and introduction, let me turn the call over to Karen Murray, General Counsel for Neo.

Seeking Alpha • Nov 14, 2025

NeoGenomics to Participate in Upcoming Investor Conferences

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the Stephens Annual Investment Conference and the Piper Sandler 37th Annual Healthcare Conference.

Business Wire • Nov 6, 2025

NeoGenomics to Present RaDaR ST Bridging Study at ISLB 2025, Demonstrating Reliable MRD Detection Across Solid Tumors

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present research at ISLB 2025 showing high concordance between its RaDaR ST and RaDaR 1.0 MRD assays, plus four additional posters.

Business Wire • Oct 30, 2025

NeoGenomics, Inc. (NEO) Q3 2025 Earnings Call Transcript

NeoGenomics, Inc. (NASDAQ:NEO ) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Priya Vedaraman Anthony Zook - CEO & Director Jeffrey Sherman - Chief Financial Officer Warren Stone - President & COO Conference Call Participants David Westenberg - Piper Sandler & Co., Research Division Andrew Brackmann - William Blair & Company L.L.C., Research Division Mason Carrico - Stephens Inc., Research Division Thomas Stevens - TD Cowen, Research Division Thomas VonDerVellen - Guggenheim Securities, LLC, Research Division Yuko Oku - Morgan Stanley, Research Division Puneet Souda - Leerink Partners LLC, Research Division Vidyun Bais - BTIG, LLC, Research Division Joseph Conway - Needham & Company, LLC, Research Division Presentation Operator Good morning, everyone, and welcome to the NeoGenomics Third Quarter 2025 Financial Results Call.

Seeking Alpha • Oct 28, 2025

NeoGenomics Reports Third Quarter 2025 Results

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics today announced its third-quarter results for the period ended September 30, 2025.

Business Wire • Oct 28, 2025

NeoGenomics (NEO) Surpasses Q3 Earnings and Revenue Estimates

NeoGenomics (NEO) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.05 per share a year ago.

Zacks Investment Research • Oct 28, 2025

NeoGenomics (NEO) Moves 6.3% Higher: Will This Strength Last?

NeoGenomics (NEO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Investment Research • Oct 16, 2025

NeoGenomics to Highlight RaDaR ST MRD Assay at ESMO Congress 2025

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will share at ESMO 2025 how its RaDaR ST MRD assay can support pharmaceutical partners across oncology research and clinical trials.

Business Wire • Oct 14, 2025